
Zydus Hospitals press release details two rare GI surgeries, including a gastric lipoma removal that may be the 28th reported. Zydus Lifesciences stock rose 0.8%.
Zydus Lifesciences (NSE: ZYDUSLIFE) shares rose 0.8% to close at ₹1,042.65 on July 28, after Zydus Hospitals, its hospital division, published a press release detailing two rare gastrointestinal surgeries.
The release, distributed through PRNewswire, described a 28-year-old woman who underwent robotic removal of a dermoid cyst wrapped around the superior mesenteric artery. Zydus Hospitals said its imaging tools and robotic platform allowed a minimally invasive approach that preserved blood supply to the small intestine. The patient was discharged three days after surgery.
A second case involved a 70-year-old breast cancer survivor with a gastric submucosal lipoma, a condition with fewer than 50 cases reported worldwide. Dr. Suril Vithalani, a surgical gastroenterologist at Zydus, performed a robotic-assisted transgastric enucleation. The hospital said the procedure was among the first done robotically for that condition.
Zydus Hospitals positioned the cases as evidence of its expertise in complex GI surgery. The release listed multiple surgeons and highlighted its diagnostic tools, including a 256-slice CT scanner and 3 Tesla MRI. It also noted a dedicated liver ICU and transplant programme.
The press release did not disclose any financial figures, patient volume data, or revenue impact from the procedures. No analyst notes referencing the release were available at the time of writing. The stock move came in a flat broader market on the same day.
Drafted by a large language model from the source reporting linked above, then screened by automated publishing checks. It is not read by a journalist before publication. Some articles cite our Alpha Score. Verify prices and figures against the original source. Educational coverage, not personalized advice.